Kereiakes, D. J., Lincoff, A. M., Anderson, K. M., Achenbach, R., Patel, K., Barnathan, E., … EPISTENT investigators. (2002). Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile. Am J Cardiol, 90(6), 628–630. https://doi.org/10.1016/s0002-9149(02)02568-7

Kereiakes, Dean J., A Michael Lincoff, Keaven M. Anderson, Robert Achenbach, Kamlesh Patel, Elliot Barnathan, Robert M. Califf, et al. “Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile.” Am J Cardiol 90, no. 6 (September 15, 2002): 628–30. https://doi.org/10.1016/s0002-9149(02)02568-7.

Kereiakes DJ, Lincoff AM, Anderson KM, Achenbach R, Patel K, Barnathan E, et al. Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile. Am J Cardiol. 2002 Sep 15;90(6):628–30.

Kereiakes, Dean J., et al. “Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile.” Am J Cardiol, vol. 90, no. 6, Sept. 2002, pp. 628–30. Pubmed, doi:10.1016/s0002-9149(02)02568-7.

Kereiakes DJ, Lincoff AM, Anderson KM, Achenbach R, Patel K, Barnathan E, Califf RM, Topol EJ, EPIC Investigators, EPILOG investigators, EPISTENT investigators. Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile. Am J Cardiol. 2002 Sep 15;90(6):628–630.